Search This Blog

Friday 18 September 2015

How dairy fats and coconut protect against type 2 diabetes


Type 2 diabetes, in the etiology laid out by Professor Roy Taylor, is (in its usual form at any rate) a condition of fat accumulation in the pancreas, liver, and muscle cells, which causes insulin resistance, hyperinsulinaemia, hyperglucagonaemia, and a vicious cycle of glucotoxicity and lipotoxicity.[1]

It is thus one of a constellation of associated lipid accumulation disorders connected with hyperinsulinaemia, the others including atherosclerosis, NAFLD, obesity. That these conditions are linked in some way was recognised as early as the 1880s by the great German physiologist Wilhelm Ebstein, the father of the modern LCHF diet.[2]

In the recent saturated fat and disease meta-analysis by de Souza et al, higher intake of ruminant trans-palmitoleic acid, a marker of dairy fat consumption, was inversely associated with type 2 diabetes (0.58, 0.46 to 0.74).[3] This is consistent with many studies of serum biomarkers of dairy fat consumption, also including odd-chain saturated fatty acids.

The recent results from Malmö, the third largest city in Sweden, give more detail about these correlations. The Malmö Diet and Cancer cohort was studied using a 7-day food diary and a 1 hour interview as well as an FFQ. This makes the results more reliable than other epidemiological diet studies, which normally use only the FFQ. In
Malmö, greater consumption of dairy fat (including butter) had a protective association with T2D. The association was strongest for shorter-chain fatty acids (from 4:0, butyrate, to 14:0, myristic acid) and there was also a protective effect of a higher ALA/LA ratio.[4]

In a separate analysis of the Malmö cohort, it was found that adherence to dietary recommendations to limit saturated fat to 14% or less of energy was associated with a 15% increased risk of T2D in men and a slightly smaller increase in women. There was a small association in men between adherence to recommendations to limit added sucrose and T2D.[5] (I see a future paper here titled “food sources of sucrose may clarify the inconsistent role of dietary sucrose intake for incidence of type 2 diabetes”. After all, chocolate consumption has beneficial associations not seen with sugar sweetened beverages.)


Is there some simple, mechanical explanation that begins to explain the relationship? If T2D is the result of excess lipid storage, are some lipids easier to store than others? NAFLD research suggests that short- to medium-chain fatty acids are not easily stored. Wistar rats fed coconut oil under NAFLD-generating conditions ate an incredible 143% extra calories across the board with no increase in hepatic lipid accumulation, while butter-fed rats managed an extra 30%.[6]

A team led by George Bray looked at rates of fatty acid oxidation in humans, and made two findings - 1) the shorter the chain length of a saturated fat, the faster the rate of oxidation, 2) the more double bonds in an unsaturated fat, the faster the rate of oxidation. Thus, lauric acid (12:0) was oxidised at a much higher rate than stearate (18:0), and ALA (18:3) was oxidised at a faster rate than LA (18:2).[7]
The faster a fatty acid is oxidised the harder it is to store; this phenomenon discourages lipid accumulation, with benefits to the risk of lipid accumulation disorders.


A second consideration is that fat displaces carbohydrate in the diet, and carbohydrate is the nutrient that, by inducing insulin secretion, increases lipid synthesis and lipid conservation, something that (without the insulin bit) Wilhelm Ebstein understood in the 1880s. Levels of serum triglycerides are directly associated with %E from carbohydrate, and this triglyceride component is the source of pancreatic fat in the model of Professor Roy Taylor.[1]

A third consideration is that saturated fats are resistant to peroxidation and oxidative stress plays a role in promoting beta-cell failure. Saturated fats are protective against beta-cell failure in the alloxan-treated rat.
http://caloriesproper.com/diet-diabetes-and-death-oh-my/



References

[1] Taylor, R. Type 2 Diabetes. Etiology and reversibility. Diabetes Care April 2013;36(4): 1047-1055

[2] Wilhelm Ebstein. Corpulence and its treatment on physiological principles. 1882. https://archive.org/details/corpulenceitstre00ebst

[3] de Souza, RJ, Mente, A, Maroleanu, A, Cozma, AI, Ha, V, Kishibe,T, et al.  Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ 2015;351:h3978

[4] Ericson, U, Hellstrand, S, Brunkwall, L, Schulz, C-A, Sonestedt, E, Wallström, P, et al. Food sources of fat may clarify the inconsistent role of dietary fat intake for incidence of type 2 diabetes. AJCN 2015;114.103010v1

[5] Sonestedt, E et al. A high diet quality based on dietary recommendations does not reduce the incidence of type 2 diabetes in the Malmo Diet and Cancer cohort. EADS2015 ePoster #322 http://www.easdvirtualmeeting.org/resources/a-high-diet-quality-based-on-dietary-recommendations-does-not-reduce-the-incidence-of-type-2-diabetes-in-the-malmo-diet-and-cancer-cohort--3

[6] Romestaing, C, Piquet, MA, Bedu, E, Rouleau, V, Dautresme, M, Hourmand-Ollivier, I et al. Long term highly saturated fat diet does not induce NASH in Wistar rats. Nutr Metab (Lond). 2007; 4: 4

[7] DeLany, JP, Windhauser, MW, Champagne, CM, Bray, GA. Differential oxidation of individual dietary fatty acids in humans. Am J Clin Nutr October 2000;72(4):  905-911

Sunday 6 September 2015

This Mendelian Randomisation - I think it does not mean what you think it means.


"LDL may or may not correlate to cardiovascular outcomes,”

-  Dr. Kim Allan Williams, president of the American College of Cardiologists

“God, grant me the serenity to accept the things I cannot change,
The courage to change the things I can,
And the wisdom to know the difference.”

- Reinhold Niebuhr’s Serenity Prayer

Last year there was a good discussion of the saturated fat issue on Otago University's Public Health Expert blog (here) that continued into the comments.
David Brown pointed out that
"Evaluation of the overall health effects of saturated fat requires consideration of markers in addition to LDL-cholesterol. Isocaloric replacement of carbohydrate with any type of fat results in decreased triglycerides and increased HDL-cholesterol, the effect on HDL-cholesterol being greater for saturated fat compared to unsaturated fat. Reductions in saturated fat also adversely affect HDL subpopulations by decreasing larger HDL2-cholesterol concentrations, whereas increases in saturated fat increase this antiatherogenic fraction. "

In response to this, Tony Blakely, professor of public health, commented
"A note of caution on HDL. An important and massive analysis of many studies published in the Lancet in 2012 found no association of HDL with myocardial infarction (or heart attacks). This study used a genetic technique call Mendelian Randomisation, which strips away (in theory, and I believe in practice in this paper) all the confounding that plagues observational studies. Thus, it appears that it is LDL – not HDL – that has a causal association with coronary heart disease.
Reference: Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet 2012;380(9841):572-80 doi: 10.1016/s0140-6736(12)60312-2[published Online First: Epub Date]|."

At the time I thought fine, when the evidence runs against your hypothesis, invent a new statistical method that obscures the fact. Nothing to see here. Then a few weeks ago Bill Barendse tweeted a paper that used Mendelian Randomisation and Bill to put it mildly has expertise in the field of genetics, so I thought it might not hurt to look into this again.

Though I am doing so in a superficial way, using logic rather than any deep understanding of the genome, I want to question whether the idea that HDL is not causal in CVD, if it is true, should make any difference at all to how we interpret risk factors or the effect of dietary or lifestyle changes.

Mendelian Randomisation is a method for identifying drug targets. If people with X polymorphism have the same cardiovascular risk as everyone else, then there's not much point in developing a drug that targets X. Fair enough - drugs that elevate HDL by tweaking the enzymes associated with it have been a big disappointment.
The problem is, the cardioprotective association of HDL remains for all that. And, as for "all the confounding that plagues observational studies", HDL is measured directly, whereas LDL is calculated in diverse ways; and it's hard to see how confounding applies to blood tests in the sense that it applies to diet epidemiology. The examples here involve controlled conditions and short-term hard outcomes in secondary prevention. This is as good as it gets - high HDL is indeed a solid marker for cardioprotection and lots of other good things (albeit the HDL increase in response to alcohol probably weakens this in some populations). Does it matter whether the HDL particle itself is protective in a causal fashion? (and, if the particle that removes cholesterol from foam cells is really a dud, where does that leave the lipid hypothesis?)
Should we rely on LDL alone to assess cardiovascular risk? (TG isn't convincingly associated with risk in Mendelian Randomisation either) Well, not if we have those other CVD risk factors, insulin resistance or type 2 diabetes.

"When compared with IS, the IR and diabetes subgroups exhibited a two- to threefold increase in large VLDL particle concentrations (no change in medium or small VLDL), which produced an increase in serum triglycerides; a decrease in LDL size as a result of an increase in small and a reduction in large LDL subclasses, plus an increase in overall LDL particle concentration, which together led to no difference (IS versus IR) or a minimal difference (IS versus diabetes) in LDL cholesterol; and a decrease in large cardioprotective HDL combined with an increase in the small HDL subclass such that there was no net significant difference in HDL cholesterol. We conclude that 1) insulin resistance had profound effects on lipoprotein size and subclass particle concentrations for VLDL, LDL, and HDL when measured by NMR; 2) in type 2 diabetes, the lipoprotein subclass alterations are moderately exacerbated but can be attributed primarily to the underlying insulin resistance; and 3) these insulin resistance-induced changes in the NMR lipoprotein subclass profile predictably increase risk of cardiovascular disease but were not fully apparent in the conventional lipid panel."

("LDL may or may not correlate to cardiovascular outcomes")

Garvey WT et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003 Feb;52(2):453-62.

Are there other interpretations of Mendelian Randomisation in the literature?

"Observed associations between serum CRP and insulin resistance, glycemia, and diabetes are likely to be noncausal. Inflammation may play a causal role via upstream effectors rather than the downstream marker CRP."

Brunner EJ et al. Inflammation, Insulin Resistance, and Diabetes—Mendelian Randomization Using CRP Haplotypes Points Upstream. Plos Medicine August 12, 2008 DOI: 10.1371/journal.pmed.0050155

In other words, those markers that don’t have genetic links to the incidence of a condition should be considered as downstream effects of the true cause. A drug that blocks CRP synthesis won’t prevent diabetes (or any other inflammatory condition) – why should it? Most likely CRP is just doing its job, and things would not suddenly be brilliant if it was removed.
Let’s walk this idea back to lipids and CVD. The TG/HDL ratio isn’t determined by your lipid genes, it’s a downstream effect of dietary carbohydrate (non-genetic) and insulin resistance (genes linked to IR and hyperglycaemia do correspond to CVD). The association between LDL and cardiovascular risk is modified by carbohydrate which increases TG-rich VLDL, the end product of which is the small, dense LDL particle, which is cleared more slowly than larger LDL particles and is thus exposed to peroxidation. Another effect of having a high output of TG-rich VLDL being that HDL gets loaded with TGs and is cleared from circulation faster (hence high TG, low HDL). Half of your LDL-associated risk can be traced to genes (like ApoE4) which you can try to tweak with drugs if you like, and half belongs to Beta-apolipoprotein, sdLDL, oxLDL etc, which are modified by the carbohydrate factor. Saturated fat effects on VLDL and LDL may differ depending on the foods they are in or the other macronutrients , especially carbohydrate.

From Siri-Tarino et al 2015

Your liver is downstream from your gut and has first pass at the nutrients you absorb there; its uptake of fats, sugars and proteins determines the triglycerides, cholesteryl esters, and apolipoptoteins the liver produces and its types of HDL and LDL species. Genetics has more influence on the LDL species than on the HDL or TG, and if you are insulin-resistant the effect of high-carbohydrate diet on HDL, TG-rich VLDL, and atherogenic LDL subspecies is magnified; this is the pathology that hyperlipidaemia, MetSyn, and diabetic lipid patterns have in common.

This is how Mendelian Randomization of LDL and HDL was presented in a recent butter and cholesterol paper [here]
“The LDL-cholesterol concentration is a true risk factor for CVD. A meta-analysis of 26 trials showed that, for every 1-mmol/L reduction in LDL cholesterol, there was a 20% relative reduction in deaths that were due to coronary heart disease (RR: 0.80; 99% CI: 0.74, 0.87) (30). Thus, our result of an increase in LDL-cholesterol concentration of 0.16 mmol/L was not negligible. In addition, butter resulted in a concomitant increase in HDL cholesterol compared with the habitual diet. An increase in HDL cholesterol of the butter diet rich in long-chain SFAs was expected because these SFAs are known to increase HDL cholesterol…
 According to the literature, the HDL cholesterol concentration is associated with a protective effect on CVD (31, 32). However, studies that used Mendelian randomization showed that genetically decreased HDL cholesterol did not increase risk of myocardial infarction and questioned a causal association between the HDL concentration and CVD (33–35). Thus, it is necessary to be careful with interpreting low HDL-cholesterol concentrations as a CVD risk factor. However, as a marker of cardiovascular health, changes in HDL cholesterol concentrations need to be included when interpreting the effect of SFAs in the diet. It is possible to speculate that an unbeneficial increase in LDL cholesterol may partly be counteracted by the beneficial effect of SFAs on HDL cholesterol, which suggests that dairy and saturated fat may be less harmful in relation to CVD than previously thought, as reported in recent meta-analysis (8, 9).”
Engel S and Thorstrup T (2015) Butter increased total and LDL cholesterol compared with olive oil however resulted in higher HDL cholesterol than habitual diet. Am J Clin Nutr. ajcn112227

Another suggestion is that HDL functionality is the important variable. HDL functionality is increased by CLA in butter and ruminant fat, olive oil polyphenols,[1] and the action of vitamin E (found in nuts and vegetable oils and other sources of linoleic acid) on protein kinase-C.[2] As substitution of all fats for carbohydrates tends to raise HDL, there will be a correspondence between intake of natural fats, HDL, and HDL functionality. Polyphenols administered without fat reduce inflammation but do not increase HDL or HDL functionality.[3]

Thus there is evidence for a rather neat correspondence between the quality of dietary fat and the cardioprotection associated with HDL -


[1] Hernáez Á et al (2014) Olive oil polyphenols enhance high-density lipoprotein function in humans: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2115-9. doi: 10.1161/ATVBAHA.114.303374. Epub 2014 Jul 24.[2] Mendez AJ et al (1990) Protein Kinase C as a Mediator of High Density Lipoprotein Receptor dependent Efflux of Intracellular Cholesterol (1990) Journal of Biological Chemistry Vol. 266, No. 16, Issue of June 5, pp. 10104-10111,199


[3] Nicod N et al (2014) Green tea, cocoa, and red wine polyphenols moderately modulate intestinal inflammation and do not increase high-density lipoprotein (HDL) production. J Agric Food Chem. 2014 Mar 12;62(10):2228-32. doi: 10.1021/jf500348u. Epub 2014 Mar 4.

From a 2014 paper that failed to find a causal relationship between HDL and CVD:

The estimates of LDL-C from instrumental variable analysis showed that a long-term genetically increased LDL-C, regardless of the analytical strategy used (unrestricted, restricted, or unrestricted score plus sequential adjustments) resulted in an increased causal OR for CHD, which is similar in magnitude to that reported in randomized trials of statin-lowering therapies in individuals at low risk of vascular disease1 and is further evidence of the validity of our various analytical approaches.For triglycerides, the findings for the unrestricted and restricted allele scores were concordant, with both showing association with CHD. However, the unrestricted score adjusted for HDL-C diminished the association to null.This could mean that a treatment that targets a triglyceride pathway that has no effect on HDL-C may not be beneficial, whereas a treatment that targets a triglyceride pathway that both reduces triglycerides and increases HDL-C could have a role in prevention of CHD events. An alternative explanation is that HDL-C could mark long-term triglyceride concentrations, but this hypothesis requires further investigation.

Holmes, MV, et al. Mendelian randomization of blood lipids for coronary heart disease. 2014. DOI: http://dx.doi.org/10.1093/eurheartj/eht571


Clearly, the complete implications of mendelian randomization for cardiovascular risk related to diet are far from clear.
But I'd putting money on this; these analyses don’t change the meanings of metabolic risk factors that are affected by diet and lifestyle, and if anything they support their usefulness as measures of improvement.